Harmony Biosciences (HRMY) to Release Earnings on Thursday

Harmony Biosciences (NASDAQ:HRMY) is projected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Harmony Biosciences to post earnings of $0.73 per share and revenue of $201.36 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Harmony Biosciences Stock Down 9.6 %

Shares of NASDAQ:HRMY opened at $35.32 on Thursday. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 16.74, a PEG ratio of 0.52 and a beta of 0.80. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 12-month low of $28.14 and a 12-month high of $41.61. The business’s 50 day moving average is $36.47 and its 200 day moving average is $35.75.

Insiders Place Their Bets

In other news, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sandip Kapadia sold 25,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. Insiders have sold 72,452 shares of company stock worth $2,831,679 in the last ninety days. 30.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

HRMY has been the topic of several research reports. Cantor Fitzgerald boosted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Needham & Company LLC lowered their target price on Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price on the stock. Oppenheimer restated an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research note on Wednesday. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $54.78.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.